LEXX Quote, Financials, Valuation and Earnings

Edesa Biotech has a net margin of -2121.06% compared to Lexaria Bioscience's net margin of --. Lexaria Bioscience's return on equity of -93.31% beat Edesa Biotech's return on equity of --.

Lexaria Bioscience has a consensus price target of --, signalling upside risk potential of 348.43%. On the other hand Edesa Biotech has an analysts' consensus of $20.50 which suggests that it could grow by 1142.42%. Given that Edesa Biotech has higher upside potential than Lexaria Bioscience, analysts believe Edesa Biotech is more attractive than Lexaria Bioscience.

Lexaria Bioscience has a beta of 1.062, which suggesting that the stock is 6.234% more volatile than S&P 500. In comparison Edesa Biotech has a beta of 0.772, suggesting its less volatile than the S&P 500 by 22.837%.

Lexaria Bioscience has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Edesa Biotech offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Lexaria Bioscience pays -- of its earnings as a dividend. Edesa Biotech pays out -- of its earnings as a dividend.

Lexaria Bioscience quarterly revenues are $84K, which are larger than Edesa Biotech quarterly revenues of --. Lexaria Bioscience's net income of -$1.8M is lower than Edesa Biotech's net income of -$962.1K. Notably, Lexaria Bioscience's price-to-earnings ratio is -- while Edesa Biotech's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Lexaria Bioscience is 59.30x versus 16.05x for Edesa Biotech. Usually stocks with elevated PS ratios are considered overvalued.

ESSA Pharma has a net margin of -2121.06% compared to Lexaria Bioscience's net margin of --. Lexaria Bioscience's return on equity of -93.31% beat ESSA Pharma's return on equity of --.

Lexaria Bioscience has a consensus price target of --, signalling upside risk potential of 348.43%. On the other hand ESSA Pharma has an analysts' consensus of -- which suggests that it could grow by 492.85%. Given that ESSA Pharma has higher upside potential than Lexaria Bioscience, analysts believe ESSA Pharma is more attractive than Lexaria Bioscience.

Lexaria Bioscience has a beta of 1.062, which suggesting that the stock is 6.234% more volatile than S&P 500. In comparison ESSA Pharma has a beta of 1.624, suggesting its more volatile than the S&P 500 by 62.388%.

Lexaria Bioscience has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. ESSA Pharma offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Lexaria Bioscience pays -- of its earnings as a dividend. ESSA Pharma pays out -- of its earnings as a dividend.

Lexaria Bioscience quarterly revenues are $84K, which are larger than ESSA Pharma quarterly revenues of --. Lexaria Bioscience's net income of -$1.8M is higher than ESSA Pharma's net income of -$6.4M. Notably, Lexaria Bioscience's price-to-earnings ratio is -- while ESSA Pharma's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Lexaria Bioscience is 59.30x versus -- for ESSA Pharma. Usually stocks with elevated PS ratios are considered overvalued.

ImmunoPrecise Antibodies has a net margin of -2121.06% compared to Lexaria Bioscience's net margin of -41.68%. Lexaria Bioscience's return on equity of -93.31% beat ImmunoPrecise Antibodies's return on equity of -68.99%.

Lexaria Bioscience has a consensus price target of --, signalling upside risk potential of 348.43%. On the other hand ImmunoPrecise Antibodies has an analysts' consensus of -- which suggests that it could grow by 1149.69%. Given that ImmunoPrecise Antibodies has higher upside potential than Lexaria Bioscience, analysts believe ImmunoPrecise Antibodies is more attractive than Lexaria Bioscience.

Lexaria Bioscience has a beta of 1.062, which suggesting that the stock is 6.234% more volatile than S&P 500. In comparison ImmunoPrecise Antibodies has a beta of 0.210, suggesting its less volatile than the S&P 500 by 79.036%.

Lexaria Bioscience has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. ImmunoPrecise Antibodies offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Lexaria Bioscience pays -- of its earnings as a dividend. ImmunoPrecise Antibodies pays out -- of its earnings as a dividend.

Lexaria Bioscience quarterly revenues are $84K, which are smaller than ImmunoPrecise Antibodies quarterly revenues of $4.5M. Lexaria Bioscience's net income of -$1.8M is higher than ImmunoPrecise Antibodies's net income of -$1.9M. Notably, Lexaria Bioscience's price-to-earnings ratio is -- while ImmunoPrecise Antibodies's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Lexaria Bioscience is 59.30x versus 0.61x for ImmunoPrecise Antibodies. Usually stocks with elevated PS ratios are considered overvalued.

Xenon Pharmaceuticals has a net margin of -2121.06% compared to Lexaria Bioscience's net margin of --. Lexaria Bioscience's return on equity of -93.31% beat Xenon Pharmaceuticals's return on equity of --.

Lexaria Bioscience has a consensus price target of --, signalling upside risk potential of 348.43%. On the other hand Xenon Pharmaceuticals has an analysts' consensus of $57.67 which suggests that it could grow by 49.05%. Given that Lexaria Bioscience has higher upside potential than Xenon Pharmaceuticals, analysts believe Lexaria Bioscience is more attractive than Xenon Pharmaceuticals.

Lexaria Bioscience has a beta of 1.062, which suggesting that the stock is 6.234% more volatile than S&P 500. In comparison Xenon Pharmaceuticals has a beta of 1.189, suggesting its more volatile than the S&P 500 by 18.926%.

Lexaria Bioscience has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Xenon Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Lexaria Bioscience pays -- of its earnings as a dividend. Xenon Pharmaceuticals pays out -- of its earnings as a dividend.

Lexaria Bioscience quarterly revenues are $84K, which are larger than Xenon Pharmaceuticals quarterly revenues of --. Lexaria Bioscience's net income of -$1.8M is higher than Xenon Pharmaceuticals's net income of -$62.8M. Notably, Lexaria Bioscience's price-to-earnings ratio is -- while Xenon Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Lexaria Bioscience is 59.30x versus 222.63x for Xenon Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.